/PRNewswire/ AuraVax Therapeutics, Inc., a biotechnology company developing novel immunotherapies to prevent and treat respiratory viruses, today announced.
/PRNewswire/ AuraVax Therapeutics, Inc., a biotechnology company developing novel immunotherapies to prevent and treat respiratory viruses, today announced.
/PRNewswire/ AuraVax Therapeutics, Inc., a biotechnology company developing novel immunotherapies to prevent and treat respiratory viruses, today announced.
AuraVax Therapeutics Enters into Exclusive License Agreement with the University of Houston for Intranasal Vaccine and Therapeutics Technology Platform Transaction supports development of AuraVax s lead COVID-19 intranasal program, plus other vaccines and therapeutics targeting respiratory diseases
News provided by
Share this article
Share this article
HOUSTON, Feb. 3, 2021 /PRNewswire/ AuraVax Therapeutics Inc. (www.auravax.com), a pioneering biotech company developing novel intranasal vaccines and therapies to help patients defeat debilitating diseases including COVID-19, today announced it has entered into an exclusive license agreement with the University of Houston (UH) with respect to the intellectual property covering a novel intranasal vaccine and STING agonist technologies. This agreement converts the optioned intellectual property between UH and AuraVax announced on October 12, 2020.
AuraVax Therapeutics Enters into Exclusive License Agreement with Massachusetts General Hospital for Intranasal Vaccine and Therapeutics Platform Transaction bolsters development of AuraVax s lead COVID-19 intranasal vaccine and strengthens platform for therapeutic development targeting a range of viral infections
News provided by
Share this article
Share this article
HOUSTON, Jan. 13, 2021 /PRNewswire/ AuraVax Therapeutics Inc. (www.auravax.com), a biotech company developing novel intranasal vaccines and therapies to help patients defeat debilitating diseases, including COVID-19, today announced it has entered into an exclusive license agreement with Massachusetts General Hospital (MGH) covering certain intellectual property and technology rights regarding compositions and discoveries of liposomal STING agonists by Mei X. Wu, PhD, of the Wellman Center for Photomedicine at MGH. Research related to this technology was published in